Journals / Dicle Tıp Dergisi / 2013 / Cilt: 40 - Sayı: 3

C-reactive protein level and obesity as cardiovascular risk factors in polycystic ovary syndrome

Polikistik over sendromunda kardiyovasküler hastalık risk faktörü olarak C-reaktif protein düzeyi ve obezite

Pages
426–431
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Struggling with obesity is one of the most important issues for preventive medicine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the role of C-reactive protein (CRP) level elevation and obesity for the increased cardiovascular disease risk in polycystic ovary syndrome (PCOS).
📊
Key Findings & Data:Methods: A hundred and nine patients with PCOS and 30 age matched healthy volunteers with regular menstrual cycle are involved in the study.
💡
Conclusion & Impact:Struggling with obesity is one of the most important issues for preventive medicine.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the role of C-reactive protein (CRP) level elevation and obesity for the increased cardiovascular disease risk in polycystic ovary syndrome (PCOS). Methods: A hundred and nine patients with PCOS and 30 age matched healthy volunteers with regular menstrual cycle are involved in the study. PCOS group is further subdivided into three subgroups according to the body mass index (BMI). Subgroups included 54 with BMI<25, 22 with BMI 25-30, and 33 with BMI>30. Blood samples for glucose, insulin, uric acid, and CRP were collected in the morning after overnight fasting (12 hours). Homeostasis model assessment-insulin resistance (HOMA-IR) was calculated. Results: Fasting blood glucose, insulin, and HOMA-IR was significantly higher in PCOS group (p=0.02, p=0.01 and p=0.02). CRP level was higher in subgroup with BMI>30. High CRP level in PCOS was found to be independent from BMI (p<0.001). HOMA-IR and insulin level was higher in the subgroup with BMI>30. When compared with the control group high insulin level was the only to be statistically significant in obese PCOS patients (p=0.005). HOMA-IR was higher in PCOS subgroup with BMI>30 when compared with controls and the PCOS subgroup with BMI<25 (p<0.001, p= 0.003). Conclusion: Obesity, hyperinsulinemia, and high CRP levels are seemed to be related and potentiating each other in PCOS. Struggling with obesity is one of the most important issues for preventive medicine.

Özet

Amaç: Bu çalışmada PKOS lu hastalarda kardiyovaskü- ler hastalık risk faktörü olarak obesite ve C-reaktif protein (CRP) seviyesinin artışını değerlendirmeyi amaçladık. Yöntemler: Çalışmamıza 109 PKOSlu ve kontrol grubu olarak benzer yaş grubundan 30 sağlıklı düzenli menstrüel siklusu olan Vücut Kitle İndeksi (VKI) 18,5-25 kg/m2 arası kadın hasta dahil edildi. PKOSlu 109 hasta VKIne göre 3 alt gruba ayrıldı. VKI 30 de olan 33 hasta çalışmada yer aldı. Hastaların 12 saat açlık sonrası sabah kan glikoz, insülin, ürik asit ve CRP düzeyleri bakıldı. HOMA-IR (Homeostatic model assesment-insulin resistance) indeksi hesaplandı. Bulgular: Açlık kan şekeri, insülin ve HOMA-IR değerleri PKOS grubunda anlamlı şekilde yüksek bulundu (p=0.02, p=0.01 ve p=0.02). VKI> 30 olanlarda CRP düzeyleri anlamlı olarak yüksek bulundu. CRP deki bu anlamlı yükseklik VKİ den bağımsız olarak saptandı (p 30 olan PKOSlu grupta HOMA-IR indeksi ve insü- lin düzeyleri diğer gruplara göre daha yüksek bulundu. Kontrol grubu ile karşılaştırıldığında insulin yüksekliği sadece obez grupta istatistiksel olarak anlamlı bulundu (p=0,005). VKİ >30 olan PKOSlu grupta kontrol ve VKİ <25 olan gruplara göre HOMA-IR indeksi daha yüksek bulundu (p<0,001, P=0,003). Sonuç: PKOSda yaygın görülen obezite, hiperinsülinemi ve artan CRP, PKOSdaki artan kardiovasküler riski göstermektedir. PKOSda kötü metabolik parametrelerin kontrolünde, obezite ile mücadele önemli bir koruyucu hekimlik konusu olarak değerlendirilmelidir

🔖

Cite This Article

ULUDAĞ, E. Ü., GÖZÜKARA, İ., KABİL, S. K., KESKİN, H., KILIÇ, H., KAMALAK, Z., KARGILI, A., ARIKAN, Ş. D. (2013). C-reactive protein level and obesity as cardiovascular risk factors in polycystic ovary syndrome. Dicle Tıp Dergisi, Cilt: 40 - Sayı: 3, 426–431. https://ajindex.com/articles/348998

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800
  2. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the South eastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078- 3082
  3. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-4011
  4. Wild RA. Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol 2002;186:35-43
  5. Pierpoint T, McKeigue PM, Isaacs AJ, et al. Mortality of women with polycystic ovary syndrome at long term follow-up. J Clin Epidemiol 1998;51:581-586
  6. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at longterm follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52:595-600
  7. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002;252:283-294
  8. Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89:2160-2165
  9. Gündüz G, Karaalp E, Süer N. The relationship between chronic inflammatory indicators that shows the risk of cardiovascular disease and HOMA-IR in patients with polycystic ovary syndrome. Turkiye Klinikleri J Gynecol Obst 2012;22:1027-1029
  10. Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev 1991;12:3-13
  11. Kirschner MA, Samojik E, Drejda M, et al. Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 1990;70:473-479
  12. Ostlund Jr RE, Staten M, Kuhrt W, et al. The ratio of waistto-hip circumference, plasma insulin level, and glucose intolerance as independent predictors for the HDL2 cholesterol level in older adults. New Engl J Med 1990;25;322:229- 234
  13. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related topolycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-417
  14. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocr